11/05/20 4:05 PMNYSE : EBSEmergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 GuidanceEmergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the three and nineRHEA-AIneutral
10/15/20 6:30 AMNYSE : EBSEmergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2020, recent business developments, revenue guidance for theRHEA-AIneutral
10/08/20 4:05 PMNYSE : EBSEmergent BioSolutions' COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent's COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19 Emergent is planning additionalRHEA-AIneutral
08/31/20 6:30 AMNYSE : EBSEmergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness DayEmergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and Mothers Against Prescription Drug Abuse (MAPDA) to highlight the importance of potentiallyRHEA-AIneutral
08/26/20 6:30 AMNYSE : EBSEmergent BioSolutions Announces Appointment of Marvin White to the Company's Board of DirectorsEmergent BioSolutions Inc. (NYSE: EBS) announced today that the company's board of directors appointed Marvin L. White as a Class II director to serve on the board effective October 1, 2020, with an initial term expiring at the 2023 annualRHEA-AIneutral
08/18/20 6:31 AMNYSE : EBSEmergent BioSolutions to Participate in Virtual Investor ConferencesEmergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following virtual investor conferences through the end of SeptemberRHEA-AIneutral
08/17/20 11:54 AMNYSE : EBSUPDATE -- Emergent BioSolutions Announces FDA Approval of NARCAN(R) (naloxone HCl) Nasal Spray Shelf Life Extension to 36 MonthsEmergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN(R) (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioidRHEA-AIvery positive
08/17/20 6:30 AMNYSE : EBSEmergent BioSolutions Announces FDA Approval of NARCAN(R) (naloxone HCl) Nasal Spray Shelf Life Extension to 36 MonthsEmergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN(R) (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioidRHEA-AIvery positive
08/07/20 4:05 PMNYSE : EBSEmergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028Emergent BioSolutions Inc. (NYSE:EBS) (the "Company") announced today that it has completed its previously announced offering of $450 million in aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (theRHEA-AIneutral
08/04/20 6:31 PMNYSE : EBSEmergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028Emergent BioSolutions Inc. (NYSE:EBS) (the "Company") announced today that it has priced its offering of $450 million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the "Notes"), representing an increase of $50 million in aggregate principal amount from the initially proposed offeringRHEA-AIneutral
